Gene Therapy companies need delivery devices for their therapies and device companies must increasingly embrace biotechnologies to improve and differentiate their increasingly commoditized offerings. In a handful of device/biotech deals signed in the pas year, device companies are gaining exclusive worldwide rights to new cardiovascular gene therapies. The next meeting ground for gene therapies and devices: orthobiologics.
More than a decade after they were first formed, gene therapy companies are still largely university research organizations in commercial disguise.
When gene therapy companies first got started, scientists believed that implanted genes could become in situfactories continually manufacturing and delivering...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
